Oppenheimer lowered the firm’s price target on Allogene Therapeutics (ALLO) to $9 from $10 and keeps an Outperform rating on the shares following quarterly results. The most notable update was that ALPHA3’s first update is being pushed back 6 months. Management said that sites were taking longer to recruit patients than anticipated-and they took full responsibility for it, the firm says.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Allogene Therapeutics price target lowered to $9 from $12 at Baird
- Buy Rating Affirmed for Allogene Therapeutics Amid Strategic Developments and Financial Strength
- Allogene Therapeutics price target lowered to $7 from $9 at Piper Sandler
- Positive Outlook on Allogene Therapeutics Amid ALPHA3 Trial Delays and Market Expansion Potential
- Allogene downgraded to Market Perform from Outperform at Citizens JMP